3d-render-human-brain-x-ray-100246610Researchers in UK found that high-dose simvastatin reduced whole-brain atrophy compared to placebo in a phase 2, randomized, double-blind, placebo-controlled, parallel trial. Patients aged 18-65 years old at the secondary progressive stage of multiple sclerosis were randomized to take either simvastatin 80 mg or placebo for 24 months. The researchers found that the adjusted difference in atrophy rate between the two groups were -0.254% per year (95% CI-0.422 to -0.087; p=0.003), which is a 43% reduction in annualized rate of atrophy. Difference between the two treatment arms were consistently seen over 0-12 months, 12-25 months, and 0-25 months. There were no differences in adverse events between the two groups.

What do you think about using high-dose simvastatin to treat secondary progressive multiple sclerosis?

Image courtesy of [Somkiat Fakmee]/FreeDigitalPhotos.net

For additional information, please visit Lancet

Advertisements